论文部分内容阅读
5月8日上午,国家食品药品监督管理局举行例行新闻发布会。据新闻发言人颜江瑛介绍,中国自主研发的注射剂“帕拉米韦三水合物”为抗病毒一类新药,2008年6月被国家食品药品监管局批准进行临床试验。目前已完成了Ⅰ期临床试验,正在开展Ⅱ期临床试验。颜江瑛说,此外,中国还有其他可用于抗病毒的化学药、中成药和中药复方制剂,且该类产品国内生产企业较多,产品质量较稳定,基本能够满足疾病预防控制工作的需求。
On the morning of May 8, the State Food and Drug Administration held a regular press conference. According to the spokesman Yan Jiangying introduction, China’s independent research and development injection “peramivir trihydrate ” as a new class of anti-virus drugs, in June 2008 by the State Food and Drug Administration approval of clinical trials. Phase I clinical trials have been completed and stage II clinical trials are underway. Yan Jiangying said that in addition, there are other chemical agents, proprietary Chinese medicines and traditional Chinese medicine preparations that can be used for antivirus treatment in China. Moreover, there are more domestic manufacturers of such products and the quality of their products is relatively stable, which basically meets the needs of disease prevention and control work.